KR20160012184A - 뉴런 세포에서의 단백질 응집체 침착을 특징으로 하는 질환을 치료하는데 사용하기 위한 타크롤리무스 - Google Patents

뉴런 세포에서의 단백질 응집체 침착을 특징으로 하는 질환을 치료하는데 사용하기 위한 타크롤리무스 Download PDF

Info

Publication number
KR20160012184A
KR20160012184A KR1020157036082A KR20157036082A KR20160012184A KR 20160012184 A KR20160012184 A KR 20160012184A KR 1020157036082 A KR1020157036082 A KR 1020157036082A KR 20157036082 A KR20157036082 A KR 20157036082A KR 20160012184 A KR20160012184 A KR 20160012184A
Authority
KR
South Korea
Prior art keywords
tacrolimus
disease
compound
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157036082A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 아콜릿체브
엘리자베쓰 밀웨이
엘리자베쓰 제인 멜러
마이클 유델
Original Assignee
크로노스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크로노스 테라퓨틱스 리미티드 filed Critical 크로노스 테라퓨틱스 리미티드
Publication of KR20160012184A publication Critical patent/KR20160012184A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020157036082A 2013-05-24 2014-05-22 뉴런 세포에서의 단백질 응집체 침착을 특징으로 하는 질환을 치료하는데 사용하기 위한 타크롤리무스 Withdrawn KR20160012184A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1309375.2 2013-05-24
GBGB1309375.2A GB201309375D0 (en) 2013-05-24 2013-05-24 Medical methods and compounds for medical use
PCT/GB2014/051570 WO2014188197A1 (en) 2013-05-24 2014-05-22 Tacrolimus for use in treating diseases characterised by protein aggregate deposition in neuronal cells

Publications (1)

Publication Number Publication Date
KR20160012184A true KR20160012184A (ko) 2016-02-02

Family

ID=48784691

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157036082A Withdrawn KR20160012184A (ko) 2013-05-24 2014-05-22 뉴런 세포에서의 단백질 응집체 침착을 특징으로 하는 질환을 치료하는데 사용하기 위한 타크롤리무스

Country Status (8)

Country Link
US (1) US20160296500A1 (https=)
EP (1) EP3003304A1 (https=)
JP (2) JP2016528171A (https=)
KR (1) KR20160012184A (https=)
CA (1) CA2910006A1 (https=)
GB (1) GB201309375D0 (https=)
SG (1) SG11201509665XA (https=)
WO (1) WO2014188197A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600376D0 (en) * 2016-01-08 2016-02-24 Chronos Therapeutics Ltd Novel therapeutic agents
US11013732B2 (en) * 2017-07-04 2021-05-25 Bionos Biotech, S.L. Use of macroazapyridinophanes metal complexes in the treatment of diseases
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
WO2023085363A1 (ja) * 2021-11-12 2023-05-19 国立大学法人長崎大学 経皮吸収型貼付剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
FR2810995A1 (fr) * 2000-06-29 2002-01-04 Exonhit Therapeutics Sa Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives
AR035411A1 (es) * 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
GB0410101D0 (en) * 2004-05-06 2004-06-09 Leuven K U Res & Dev Parkinson's disease
EP1810675A1 (en) * 2006-01-18 2007-07-25 Institut Curie Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
JP2012171895A (ja) * 2011-02-18 2012-09-10 Nagoya City Univ 毛細血管拡張性失調症治療薬及びその用途

Also Published As

Publication number Publication date
JP2016528171A (ja) 2016-09-15
CA2910006A1 (en) 2014-11-27
JP2019104746A (ja) 2019-06-27
EP3003304A1 (en) 2016-04-13
US20160296500A1 (en) 2016-10-13
WO2014188197A1 (en) 2014-11-27
SG11201509665XA (en) 2015-12-30
GB201309375D0 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
Cummings et al. Alzheimer’s disease: novel targets and investigational drugs for disease modification
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
AU2013295370B2 (en) Use of biotin for the treatment of multiple sclerosis
JP6437119B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP2019104746A (ja) 神経細胞におけるタンパク質凝集体の沈着を特徴とする疾患の治療に使用するためのタクロリムス
US8334262B2 (en) Cognitive function
KR20160062222A (ko) 샤르코-마리-투스 질환 관련 장애를 치료하기 위한 필로카핀 및 메티마졸 조합
WO2009102021A1 (ja) 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療
JP2020172530A (ja) 認知症の症状が観察されない患者の認知症の発症を遅らせるための薬剤
CN111973592A (zh) 治疗肌萎缩侧索硬化和神经病的方法
KR101111411B1 (ko) 당뇨병성 황반증의 예방 또는 치료제
US9789092B2 (en) Biotin for use in treating X-linked adrenoleukodystrophy
US11969397B2 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
US20120010264A1 (en) Novel medicament for treating cognitive impairment
US20250255885A1 (en) Use of steroid compound in preparing drugs for preventing and/or treating presbyopia
US20160120853A1 (en) Tacrolimus and analogues thereof for medical use
KR20180102086A (ko) Tdp-43 단백질병증의 치료를 위한 타크로리무스
WO2022263624A1 (en) Novel compounds for the treatment and prevention of neurological complications of viral infections
US20180085356A1 (en) Method of treating disease characterised by protein aggregate deposition in neuronal cells
Ciobica et al. P3. 115 A possible correlation between memory and neuronal oxidative stress status in a 6-OHDA model of Parkinson's disease
US20130236447A1 (en) Cognitive function
WO2014188199A1 (en) Tacrolimus and analogues thereof for treating osteoporosis
EP2991645A1 (en) Biotin for use in treating x-linked adrenoleukodystrophy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190522

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20200819

WITB Written withdrawal of application